Press releases

Advanced Pharmaceutical Manufacturing (APM), an emerging leader in drug production technologies, has announced the establishment of a new state-of-the-art manufacturing facility in Singapore. This cutting-edge facility is set to transform the local pharmaceutical landscape by significantly increasing production capacity and improving operational efficiencies.

The decision to expand operations comes on the heels of rising demand for both generic and specialty pharmaceuticals in the Asia-Pacific region. The new facility is designed to meet stringent international regulatory standards, ensuring that APM continues to deliver high-quality medicines to global markets.

"This new manufacturing facility represents a pivotal moment for Advanced Pharmaceutical Manufacturing as we strategically position ourselves to meet growing market needs," commented Jane Smith, COO of APM. "With the integration of advanced automation technologies and lean manufacturing principles, we anticipate not only an increase in efficiency but also a significant reduction in our environmental footprint."

The new site will utilize cutting-edge manufacturing equipment, including continuous manufacturing systems and robotics, further showcasing APM's commitment to innovation. The facility will be equipped to handle both small-scale and large-scale production, making it adaptable to varying client demands while ensuring consistency and reliability in output.

Furthermore, the Singapore facility will play a critical role in APM's research and development initiatives. The company plans to work closely with local universities and research institutions to foster innovation and develop new formulations and delivery methods that meet the diverse needs of healthcare providers worldwide.

As part of its global strategy, APM is committed to enhancing its value proposition for clients by ensuring rapid response times and flexibility in changing market conditions. The new facility is expected to create numerous job opportunities in the region, boosting local employment rates and contributing to the economy.

Regulatory compliance remains a top priority as the facility seeks to become a recognized center of excellence. APM has instituted comprehensive training programs for staff to maintain the highest standards of quality assurance throughout the manufacturing process. This commitment ensures that all products meet or exceed regulatory requirements, supporting the company’s mission to deliver safe and effective medications.

Looking ahead, APM is exploring potential partnerships with other industry players to expand its offerings and capabilities. The new facility will serve as a focal point for collaborations that can enhance drug development, increase efficiencies, and drive innovation in the pharmaceutical manufacturing sector.

"We are excited about the prospects that our new facility brings, not just for Advanced Pharmaceutical Manufacturing but for the broader pharmaceutical community in Singapore," added Smith. "By investing in advanced technologies and training, we are ensuring that we remain at the forefront of pharmaceutical innovation and remain responsive to our clients' needs."

The Singapore facility is projected to begin operations by early 2026, with phased production rollout based on market demand and regulatory approvals. This ambitious expansion marks a critical step in APM’s journey toward becoming a global leader in pharmaceutical manufacturing.